

## **ASX Announcement**

# **Change of Director's Interest Notice**

**Melbourne, Australia; 3 May 2021:** Mach7 Technologies Limited (ASX:M7T), a company specialising in innovative data management solutions for healthcare providers, provides Appendix 3Y - Change of Director's Interests Notice for CEO & Managing Director, Mike Lampron.

Mike Lampron has recently exercised 116,667 options and sold 116,607 of the resulting shares on-market. The reason for the transaction is to enable Mike to meet a US tax obligation by May 15, 2021.

This announcement has been approved for lodgment by the Company Secretary.

### **About Mach7 Technologies:**

Mach7 Technologies (ASX:M7T) develops innovative data management solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced clinical viewing and optimized vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit Mach7t.com.

## For more information, contact:

Jenni Pilcher CFO, Mach7 jenni.pilcher@mach7t.com Andrew Keys Investor Relations andrew.keys@keysthomas.com Registered Office: Level 2, 20 Collins Street Melbourne, 3000



Rule 3.19A.2

# **Appendix 3Y Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Mach7 Technologies Limited	
ABN	26 007 817 192	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mike Lampron
Date of last notice	2 December 2020

## Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)  Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	26 & 30 April 2021
No. of securities held prior to change	1,450,000 unlisted options 85,148 fully paid ordinary shares 378,114 Performance Rights
Class	Unlisted Options Fully Paid Ordinary Shares
Number acquired	116,667 Fully Paid Ordinary Shares
Number disposed	116,607 Fully Paid Ordinary Shares Sold 116,667 Unlisted Options Exercised
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$0.175 per Share acquired upon exercise of options \$1.207 per Share disposed
No. of securities held after change	1,333,333 unlisted options 85,208 fully paid ordinary shares 378,114 Performance Rights

<sup>+</sup> See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of options, and on-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

N/A N/A
·
N/A
N/A

## Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.